[The pharmacology of (+/-)-1-(4-cyclohexylureido-phenoxy)-2-hydroxy-3-tert-butylaminopropane (Talinolol, Cordanum, 02-115)].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D002415:Cats; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009200:Myocardial Contraction / Q000187:drug effects; D011217:Practolol / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives; D014590:Uterine Contraction / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C011550:talinolol; D014508:Urea; D011433:Propranolol; D011217:Practolol
Zur Pharmakologie von (+/-)-1-[4-Cyclohexylureidophenoxy]-2-hydroxy-3-tert.-butylaminopropan (Talinolol, Cordanum, 02-115)